How safe is a standard-risk child with ALL?

Lancet Oncol. 2014 Jul;15(8):782-3. doi: 10.1016/S1470-2045(14)70294-3. Epub 2014 Jun 19.

Authors

Jeanette Falck Winther¹, Kjeld Schmiegelow²

Affiliations

¹ Danish Cancer Society Research Center, Copenhagen, DK 2100, Denmark. Electronic address: jeanette@cancer.dk.
² Pediatrics and Adolescence Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark; Institute for Clinical Medicine, University of Copenhagen, Denmark.

PMID: 24954780
DOI: 10.1016/S1470-2045(14)70294-3

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Female
Humans
Male
Neoplasms, Second Primary / epidemiology*
Population Surveillance*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality*